Legal & General Group Plc lessened its stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 5.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 68,311 shares of the health services provider's stock after selling 3,615 shares during the quarter. Legal & General Group Plc owned about 0.21% of Amedisys worth $6,202,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Blue Trust Inc. grew its position in Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock worth $34,000 after acquiring an additional 124 shares during the last quarter. Xponance Inc. boosted its stake in shares of Amedisys by 3.5% during the fourth quarter. Xponance Inc. now owns 4,349 shares of the health services provider's stock valued at $395,000 after purchasing an additional 148 shares in the last quarter. Inspire Investing LLC grew its holdings in shares of Amedisys by 3.6% during the fourth quarter. Inspire Investing LLC now owns 4,405 shares of the health services provider's stock worth $400,000 after purchasing an additional 155 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in Amedisys by 1.2% in the 4th quarter. Nisa Investment Advisors LLC now owns 15,150 shares of the health services provider's stock valued at $1,375,000 after buying an additional 180 shares during the last quarter. Finally, Retirement Systems of Alabama boosted its position in Amedisys by 0.5% during the 4th quarter. Retirement Systems of Alabama now owns 39,822 shares of the health services provider's stock worth $3,615,000 after buying an additional 181 shares during the period. Institutional investors own 94.36% of the company's stock.
Amedisys Trading Up 0.7 %
AMED traded up $0.64 during trading on Thursday, hitting $94.27. The company's stock had a trading volume of 382,845 shares, compared to its average volume of 320,959. The firm has a market capitalization of $3.09 billion, a P/E ratio of 37.41, a PEG ratio of 1.78 and a beta of 0.89. Amedisys, Inc. has a twelve month low of $82.15 and a twelve month high of $98.95. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The stock's fifty day moving average price is $92.14 and its 200-day moving average price is $91.84.
Amedisys (NASDAQ:AMED - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.12. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business had revenue of $594.78 million for the quarter, compared to analyst estimates of $597.43 million. Analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current year.
Analyst Upgrades and Downgrades
AMED has been the subject of a number of recent research reports. Stephens restated an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a report on Tuesday, March 4th. Royal Bank of Canada reiterated an "outperform" rating and issued a $100.00 target price on shares of Amedisys in a report on Wednesday, April 16th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Amedisys currently has an average rating of "Hold" and an average target price of $100.75.
Check Out Our Latest Stock Report on Amedisys
Amedisys Profile
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Articles

Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.